Under Armour reports revenue decline, misses earnings estimates, and forecasts further sales drop amid inflation and weaker consumer spending.
Analysts warn of multiple risky stocks amid industry headwinds, with caution toward firms relying on volatile assets and outdated models.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.
Under Armour reports revenue decline, misses earnings estimates, and forecasts further sales drop amid inflation and weaker consumer spending.
Analysts warn of multiple risky stocks amid industry headwinds, with caution toward firms relying on volatile assets and outdated models.
Gilead Sciences reports strong Q2 2025 results, raises full-year guidance, and sees its stock surge to a 7-year high amid optimism about its strategy and pipeline momentum.